PMPRB releases new Guidelines to monitor and review drug prices

News Release

For Immediate Release

June 30, 2025 — Ottawa, ON — Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff today. They will take effect on January 1, 2026. The Guidelines explain the new two-step process used by PMPRB staff to monitor and review drug prices by comparing them to the prices in other countries or to other similar treatments in Canada. If a drug's price raises concerns, PMPRB staff may recommend a hearing to the Chair. These new Guidelines have been established following a comprehensive consultation process, after much consideration from the Board. They depart significantly from previous Guidelines.

As per the new Guidelines, the PMPRB will follow a two-step review process. The Initial or Annual Review serves as a screening process. If this step raises concerns, or if a complaint is received from an approved individual or organization, the PMPRB will then start a more in-depth review. During an In-Depth Review the PMPRB staff compare the drug under review to similar drugs and treatments available for the same medical conditions.

The PMPRB plays a unique and important role in the Canadian health system by ensuring that prices of patented medicines are not excessive. The Guidelines provide a transparent and predictable process to be used by PMPRB staff to review drug prices once they enter the market.